title: Post-injury delivery of rAAV2-CNTF combined with short-term pharmacotherapy is neuroprotective and promotes extensive axonal regeneration after optic nerve trauma.
abstract: Recombinant adeno-associated viral (rAAV) vectors expressing neurotrophic genes reduce neuronal death and promote axonal regeneration in central nervous system (CNS) injury models. Currently, however, use of rAAV to treat clinical neurotrauma is problematic because there is a delay in the onset of transgene expression. Using the adult rat retina and optic nerve (ON), we have tested whether rAAV gene therapy administered at the time of injury combined with short-term pharmacotherapy has synergistic effects that enhance neuronal survival and regeneration. The ON was transected and a 1.5 cm segment of autologous peripheral nerve (PN) was grafted onto the cut end. At this time, bicistronic rAAV2 encoding ciliary neurotrophic factor (CNTF) and green fluorescent protein (rAAV2-CNTF-GFP) was injected into the injured eye. To provide interim support for axotomized retinal ganglion cells (RGCs) during vector integration and therapeutic transgene expression, rCNTF protein and a cyclic adenosine monophosphate (cAMP) analogue (CPT-cAMP) were injected intravitreally 3 and 10 days postoperatively. For comparison, another rAAV2-CNTF-GFP group received two intravitreal saline injections 3 and 10 days after the PN-ON surgery. A further PN graft group received only postoperative intravitreal injections of rCNTF plus CPT-cAMP. After 4 weeks, regenerating RGCs were retrogradely labelled by applying fluorogold to the distal end of each PN graft. Compared to saline-injected animals, both RGC survival and axonal regrowth were significantly higher in the rCNTF and CPT-cAMP injected rAAV2-CNTF-GFP group; approximately one third of the RGC population survived axotomy, and 27% of these regrew an axon. These values were also higher than those obtained in rats that received only rCNTF plus CPT-cAMP injections. Therefore, we show for the first time that rAAV-mediated gene delivery at the time of, or just after, neurotrauma is most successful when combined with temporary post-injury trophic support, and is potentially a viable treatment strategy for patients after acute CNS injury.
authors.affiliation: School of Anatomy and Human Biology, The University of Western Australia, Crawley, Western Australia, Australia.
authors.forename: Mats
authors.initials: M
authors.lastname: Hellström
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Pollett
authors.forename: Alan R
authors.initials: AR
authors.lastname: Harvey
mesh_terms: D000818:Animals; D001369:Axons / Q000473:pathology / Q000502:physiology*; D020934:Ciliary Neurotrophic Factor / Q000008:administration & dosage* / Q000235:genetics; D000242:Cyclic AMP / Q000008:administration & dosage / Q000235:genetics; D000229:Dependovirus / Q000235:genetics; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D009416:Nerve Regeneration / Q000235:genetics*; D020221:Optic Nerve Injuries / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D020934:Ciliary Neurotrophic Factor; D011993:Recombinant Fusion Proteins; D000242:Cyclic AMP